Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinsonian's disease and other neurodegenerative diseases in Australia. The company's lead drug candidates is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 for used as an antimicrobial agent. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. The company was founded in 1997 and is based in Melbourne, Australia.
IPO Year:
Exchange: NASDAQ
Website: alteritytherapeutics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/3/2025 | Speculative Buy → Hold | The Benchmark Company | |
| 12/12/2024 | $8.00 | Buy | Maxim Group |
| 8/20/2021 | $4.00 | Speculative Buy | Benchmark |